导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 2.83% | 1740/4773 |
| 近一周 | -1.18% | 1775/5465 |
| 近一月 | -8.04% | 4748/5421 |
| 近一季 | -18.13% | 4694/5231 |
| 近半年 | -1.35% | 1752/4920 |
| 近一年 | 6.58% | 1577/4394 |
| 近两年 | 113.11% | 493/2954 |
| 近三年 | 68.10% | 371/2253 |
| 成立以来 | 81.92% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.07% 2103/4961 |
33.68% 975/5312 |
- - |
- - |
| 2025 | 47.84% 549/4813 |
-1.41% 2662/3635 |
3.10% 1166/4076 |
46.74% 519/4524 |
-0.89% 2696/4813 |
| 2024 | 16.51% 800/3463 |
-3.67% 1540/2808 |
-6.06% 1841/3014 |
27.49% 220/3129 |
0.99% 1142/3463 |
| 2023 | -17.99% 1773/2656 |
2.07% 1456/2280 |
-6.87% 1732/2385 |
-9.04% 1771/2515 |
-5.15% 1269/2655 |
| 2022 | -27.91% 1515/2207 |
-18.93% 1413/1919 |
5.55% 879/2016 |
-17.50% 1606/2113 |
2.11% 1036/2208 |
| 2021 | 10.56% 430/1822 |
-6.55% 1016/1255 |
24.14% 111/1330 |
-6.50% 942/1466 |
1.93% 748/1822 |
| 2020 | 59.97% 125/1250 |
3.86% 106/1028 |
28.33% 110/1067 |
5.20% 926/1164 |
14.10% 298/1184 |
| 2019 | 40.25% 258/1092 |
32.48% 172/739 |
-9.94% 705/788 |
7.04% 105/850 |
9.82% 190/918 |
| 2018 | - - |
- - |
-11.92% 373/631 |
-10.95% 555/660 |
-10.78% 226/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 工银创业板ETF联接C VS. 长安沪深300非周期A(740101) |